Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, how many breast cancer clinicians he spoke to directly when developing his policy on the Off-patent Drugs Bill.

In developing our response to the Bill, we have taken advice from a number of cancer clinicians including breast cancer specialists and from officials at the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency, and taken account of views expressed by other stakeholder organisations.